Gary K. Scott

7.9k total citations · 3 hit papers
64 papers, 6.4k citations indexed

About

Gary K. Scott is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Gary K. Scott has authored 64 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Molecular Biology, 19 papers in Oncology and 15 papers in Cancer Research. Recurrent topics in Gary K. Scott's work include Estrogen and related hormone effects (11 papers), Histone Deacetylase Inhibitors Research (9 papers) and HER2/EGFR in Cancer Research (8 papers). Gary K. Scott is often cited by papers focused on Estrogen and related hormone effects (11 papers), Histone Deacetylase Inhibitors Research (9 papers) and HER2/EGFR in Cancer Research (8 papers). Gary K. Scott collaborates with scholars based in United States, Canada and Switzerland. Gary K. Scott's co-authors include Christopher C. Benz, Dipa Bhaumik, Crystal Berger, Arturo V. Orjalo, Judith Campisi, Michael Mattie, Andrei Goga, Christopher S. Sullivan, Daryl C. Drummond and Zexiong Guo and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Gary K. Scott

63 papers receiving 6.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

1992 625 citations Christopher C. Benz, Gary K. Scott et al. Breast Cancer Research and Treatment profile →
Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies.

2006 589 citations Michael Mattie, Christopher C. Benz et al. profile →
Coordinate Suppression of ERBB2 and ERBB3 by Enforced Expression of Micro-RNA miR-125a or miR-125b

2006 525 citations Gary K. Scott, Dipa Bhaumik et al. Journal of Biological Chemistry profile →

Peers

Gary K. Scott

ONCOL

GENET

IMMUN

Nicholas C. Popescu United States

Viji Shridhar United States

Douglas S. Darling United States

Akihiro Kurimasa Japan

Roberto D. Polakiewicz United States

Roseline Godbout Canada

Jaime A. Escobedo United States

Sean E. Egan Canada

Peter van der Geer United States

Edurne Berra France

Nicholas C. Popescu United States

Gary K. Scott

5.6k ×1.2

1.4k ×0.6

1.9k ×1.2

ONCOL

948 ×1.2

GENET

628 ×1.0

IMMUN

Citations per year, relative to Gary K. Scott Gary K. Scott (= 1×) peers Nicholas C. Popescu

Countries citing papers authored by Gary K. Scott

Since Specialization

Citations

This map shows the geographic impact of Gary K. Scott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary K. Scott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary K. Scott more than expected).

Fields of papers citing papers by Gary K. Scott

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary K. Scott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary K. Scott. The network helps show where Gary K. Scott may publish in the future.

Co-authorship network of co-authors of Gary K. Scott

This figure shows the co-authorship network connecting the top 25 collaborators of Gary K. Scott. A scholar is included among the top collaborators of Gary K. Scott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary K. Scott. Gary K. Scott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Scott, Gary K., et al.. (2025). Biochemical, structural, and cellular characterization of S-but-3-yn-2-ylglycine as a mechanism-based covalent inactivator of the flavoenzyme proline dehydrogenase. Archives of Biochemistry and Biophysics. 765. 110319–110319.

Tanner, John J., Gary K. Scott, Javier Seravalli, et al.. (2024). Noncovalent Inhibition and Covalent Inactivation of Proline Dehydrogenase by Analogs of N-Propargylglycine. Biochemistry. 63(21). 2855–2867. 3 indexed citations

Bons, Joanna, Gary K. Scott, John J. Tanner, et al.. (2023). Therapeutic targeting of HYPDH/PRODH2 with N-propargylglycine offers a Hyperoxaluria treatment opportunity. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1870(1). 166848–166848. 3 indexed citations

Scott, Gary K., Christina Yau, Sophia Mahoney, et al.. (2019). Targeting Mitochondrial Proline Dehydrogenase with a Suicide Inhibitor to Exploit Synthetic Lethal Interactions with p53 Upregulation and Glutaminase Inhibition. Molecular Cancer Therapeutics. 18(8). 1374–1385. 37 indexed citations

Held, Jason M., David J. Britton, Gary K. Scott, et al.. (2012). Ligand Binding Promotes CDK-Dependent Phosphorylation of ER-Alpha on Hinge Serine 294 but Inhibits Ligand-Independent Phosphorylation of Serine 305. Molecular Cancer Research. 10(8). 1120–1132. 26 indexed citations

Sadanandam, Anguraj, Aseem Lal, Stephen C. Benz, et al.. (2012). Genomic aberrations in normal tissue adjacent to HER2-amplified breast cancers: field cancerization or contaminating tumor cells?. Breast Cancer Research and Treatment. 136(3). 693–703. 11 indexed citations

An, Mahru C., Ningzhe Zhang, Gary K. Scott, et al.. (2012). Genetic Correction of Huntington's Disease Phenotypes in Induced Pluripotent Stem Cells. Cell stem cell. 11(2). 253–263. 284 indexed citations

Orjalo, Arturo V., et al.. (2009). Cell surface-bound IL-1α is an upstream regulator of the senescence-associated IL-6/IL-8 cytokine network. Proceedings of the National Academy of Sciences. 106(40). 17031–17036. 492 indexed citations

Suzuki, Junko, Yunn-Yi Chen, Gary K. Scott, et al.. (2009). Protein Acetylation and Histone Deacetylase Expression Associated with Malignant Breast Cancer Progression. Clinical Cancer Research. 15(9). 3163–3171. 106 indexed citations

10.

Marx, Corina, Christina Yau, Surita Banwait, et al.. (2007). Proteasome-Regulated ERBB2 and Estrogen Receptor Pathways in Breast Cancer. Molecular Pharmacology. 71(6). 1525–1534. 22 indexed citations

11.

Marx, Corina, Crystal Berger, Stephen C. Benz, et al.. (2006). Therapeutic destabilization of ErbB2 transcripts mediated by U-rich mRNA binding proteins and microRNAs.. Cancer Research. 66. 1320–1320. 1 indexed citations

12.

Scott, Gary K., et al.. (2004). Proteasome and histone deacetylase inhibitors repress ErbB2 transcript levels and additively inhibit breast cancer growth.. Cancer Research. 64. 566–566. 1 indexed citations

13.

Zhou, Yamei, Serenella Eppenberger‐Castori, Corina Marx, et al.. (2004). Activation of nuclear factor-κB (NFκB) identifies a high-risk subset of hormone-dependent breast cancers. The International Journal of Biochemistry & Cell Biology. 37(5). 1130–1144. 113 indexed citations

14.

Scott, Gary K., et al.. (2002). Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen.. Molecular Cancer Therapeutics. 1(6). 385–92. 55 indexed citations

15.

Quong, Judy N., Serenella Eppenberger‐Castori, Dan H. Moore, et al.. (2002). Age-Dependent Changes in Breast Cancer Hormone Receptors and Oxidant Stress Markers. Breast Cancer Research and Treatment. 76(3). 221–236. 56 indexed citations

16.

Lü, Biao, Xiaoshan Liang, Gary K. Scott, et al.. (1998). Polyamine inhibition of estrogen receptor (ER) DNA-binding and ligand-binding functions. Breast Cancer Research and Treatment. 48(3). 243–257. 17 indexed citations

17.

Benz, Christopher C., Rónán C. O’Hagan, B. Diane Richter, et al.. (1997). HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene. 15(13). 1513–1525. 142 indexed citations

18.

Scott, Gary K., Janice C. Daniel, Xiaohui Xiong, et al.. (1994). Binding of an ETS-related protein within the DNase I hypersensitive site of the HER2/neu promoter in human breast cancer cells.. Journal of Biological Chemistry. 269(31). 19848–19858. 78 indexed citations

19.

Noonberg, Sarah B., Gary K. Scott, C. Anthony Hunt, Michael E. Hogan, & Christopher C. Benz. (1994). Inhibition of transcription factor binding to the HER2 promoter by triplex-forming oligodeoxyribonucleotides. Gene. 149(1). 123–126. 43 indexed citations

20.

Scott, Gary K., et al.. (1993). Human breast tumors containing non-DNA-binding immunoreactive (67 kDa) estrogen receptor. Breast Cancer Research and Treatment. 26(2). 181–189. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact